Temozolomide, an orally administered alkylating agent, is used to treat malignant gliomas.
Recent reports also have documented its efficacy in the treatment of pituitary adenomas and …

Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently,
aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and …

Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Pituitary tumors are amongst the most common intracranial neoplasms and are generally
benign. However, some pituitary tumors exhibit clinically aggressive behavior that is …

Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since
2006. It is inexpensive and well tolerated, the main side effects are fatigue, nausea and …

Context: The typically indolent behavior of pituitary tumors is juxtaposed with high rates of
tumor cell invasion into adjacent dural structures, and occasional aggressive behavior …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Recent case reports have documented the efficacy of temozolomide therapy in some
aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy …

Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine
neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in …